RedHill announces new Chinese patent notice of allowance for opaganib

RedHill Biopharma announced the issue of a new Chinese patent notice of allowance for opaganib in combination with immune checkpoint inhibitors as a method of inducing an anti-cancer immune response, providing protection for opaganib’s potential use with a range of approved and in-development immune checkpoint inhibitors across a growing range of indications through 2040. The patent will be issued by the Chinese National Intellectual Property Administration, CNIPA. Guy Goldberg, RedHill’s Chief Business Officer, said, “This exciting new patent is based on compelling data from a range of in vivo experiments showing significant improvements in outcomes in combination with selected ICIs. China has been a world leader in embracing ICI-based therapy and this is an important addition to the strong patent portfolio protecting opaganib.”